Genmab — Marts 2022
-
God morgen.
-
https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/capital-markets-day-2022/P6-rare-disease.pdf novonordisk CMD- Rare disease presentation containing
Mim8 -
https://www.proinvestor.com/boards/97931#postdiv101614
Ugekortet begynder, at indikere bedre tider. Baseret på historisk mønster ligner det optur frem til September. Salgspresset er aftagende (lyserøde stage som bliver mindre for hver uge). Så vi går en spændende tid i møde med mulighed for ny ATH i Q3. -
Genmabs geniale partnerskaber belønnes ikke af investorerne
Mens Genmab for længst har manifesteret sig som et verdensklasse biotek-power-house, der skaber blockbuster-medicin på samlebånd, så fremstår investorerne stadig tøvende, når virksomheden poster nye milliarder i den tidlige pipeline, og potentialet af de store partnerskaber skal forstås, skriver analytiker David Mygind i denne analyse, som er udarbejdet i samarbejdet med Økonomisk Ugebrev Life Science. […]
Økonomisk Ugebrev (ugebrev.dk)
-
A bispecific targeting PD-L1 and 4-1BB shows potential from culture to clinic https://acir.org/weekly-digests/2022/march/a-bispecific-targeting-pd-l1-and-4-1bb-shows-potential-from-culture-to-clinic (based on recent Cancer Discovery article
)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind